Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma
NCT00553644Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2007
- Primary completion
- Dec 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and bortezomib in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate up to 6 years and Complete Response Rate up to 6 years. Started Nov 2007; status: completed.
02
Drugs
lenalidomidebortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00553644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553644.